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        Leukocyte-expressed orphan heptahelical recep-
tors that share signifi  cant homology with known 
chemoattractant receptors, yet remain uncharac-
terized with respect to ligand binding properties 
and functions, represent excellent candidates for 
additional regulators of immune cell traffi   cking 
and function. Given its phylogenetic homology 
with members of the CC chemokine receptor 
subfamily, orphan serpentine receptor chemo-
kine (CC motif) receptor-like 2 (CCRL2; also 
known as L-CCR [LPS-inducible C-C chemo-
kine receptor related gene] or Eo1 in mice, and 
HCR [human chemokine receptor], CRAM-A, 
CRAM-B, or CKRX [chemokine receptor X] 
in humans) has been identifi  ed as a potential 
leukocyte chemoattractant receptor. However, 
CCRL2 possesses an uncharacteristic intracellular 
loop 2 sequence in place of the DRYLAIV motif 
generally found in signaling chemokine receptors 
(QRYLVFL in huCCRL2 and QRYRVSF in 
mCCRL2), leading us to postulate that it might 
be an   “  atypical  ”   silent or nonsignaling receptor. 
From a phylogenetic standpoint, CCRL2 may 
be unique, as its orthologues are more divergent 
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  Mast cells contribute importantly to both protective and pathological IgE-dependent 
immune responses. We show that the mast cell  –  expressed orphan serpentine receptor 
mCCRL2 is not required for expression of IgE-mediated mast cell  –  dependent passive cuta-
neous anaphylaxis but can enhance the tissue swelling and leukocyte infi  ltrates associated 
with such reactions in mice. We further identify chemerin as a natural nonsignaling protein 
ligand for both human and mouse CCRL2. In contrast to other   “  silent  ”   or professional 
chemokine interreceptors, chemerin binding does not trigger ligand internalization. Rather, 
CCRL2 is able to bind the chemoattractant and increase local concentrations of bioactive 
chemerin, thus providing a link between CCRL2 expression and infl  ammation via the cell-
signaling chemerin receptor CMKLR1. 
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to other chemokine receptors (  16  ). Endothelial cell  –  expressed 
DARC may be able to transcytose certain chemokines, al-
though this fi  nding is controversial (  17, 18  ). CCX-CKR 
mRNA is expressed in many tissues, including lymph node, 
spleen, placenta, kidney, brain, and by leukocytes. It binds 
the homeostatic chemokines CCL19, CCL21, and CXCL13 
and has been shown to be able to degrade large quantities 
of CCL19 (  19  ). Genetic defi  ciencies in D6 or DARC have 
been associated with exacerbated or dysregulated infl  am-
matory responses, refl  ecting the importance of interceptors in 
dampening chemokine-mediated activities (for review see 
reference   10  ). 
  We and others identifi  ed chemerin as a natural nonche-
mokine chemoattractant ligand for chemokine-like receptor-
1 (CMKLR1) (  20  –  22  ). CMKLR1 is expressed by circulating 
human plasmacytoid DC (pDC) but not by circulating or 
tissue mouse DC (  20, 23  ). In contrast, tissue resident macro-
phages in both humans and mice express CMKLR1 (  23  ). A 
recent study by Parolini et al. (  24  ) describes CMKLR1 expres-
sion by human NK cells. We and others have demonstrated 
that activation of chemerin involves proteolytic processing 
of the carboxyl terminus and removal of inhibitory amino 
acids (  22, 25  –  27  ; for review see reference   28  ). Various serine 
proteases of the coagulation, fi  brinolytic, and infl  ammatory 
cascades can activate chemerin, including plasmin, factor XII, 
and neutrophil elastase and cathepsin G (  27  ). Mast cell trypt-
ase, released upon antigen-mediated cross-linking of surface 
IgE/Fc     RI on mast cells, is a particularly potent activator 
of chemerin (  27  ). We have also demonstrated that chemerin 
circulates at low nanomolar concentrations in plasma in an 
immature inactive proform (for review see reference   28  ). We 
hypothesize that chemerin may serve as a nearly ubiquitous 
  “  humor  ”   poised to translate tissue damage or bleeding into 
rapidly generated attractant fi  elds for specialized CMKLR1-
positive cells. 
  Mast cells, tissue-dwelling derivatives of circulating mast 
cell progenitors, are anatomically deployed to host-environment 
boundaries (such as the skin, airways, and alimentary canal) 
where they can mediate fi  rst-line encounters with pathogens 
and environmental allergens (  29  ). Antigen-mediated cross-
linking of surface IgE/Fc     RI triggers mast cell degranulation 
and the release of preformed proinfl  ammatory mediators 
stored in the cells  ’   cytoplasmic granules, such as histamine, 
heparin, and proteases (e.g., tryptases, chymases, and cathep-
sins), and initiates the synthesis and release of lipid mediators 
(e.g., prostaglandin D  2   and leukotrienes) and diverse cytokines, 
chemokines, and growth factors (  30  ). Localized IgE-mediated 
mast cell   “  anaphylactic-type  ”   degranulation can be modeled 
in vivo by experimental IgE-dependent passive cutaneous ana-
phylaxis (PCA) in mice. 
  In this paper, we generated novel mAbs specifi  c for the 
orphan GPCR mCCRL2 and demonstrated that freshly iso-
lated mouse peritoneal mast cells selectively express the re-
ceptor. mCCRL2 KO mice displayed no overt phenotype and 
had normal numbers of mast cells in the tissues analyzed. When 
tested in vitro, BM-derived cultured mast cells (BMCMCs) 
in sequence that any other mouse-to-man receptor pair in 
the chemoattractant G protein  –  coupled receptor (GPCR) sub-
family. The sequence identity of mouse and human CCRL2 is 
only 51%, compared with     80% identity between most other 
receptor orthologues (  1  –  3  ). 
  mCCRL2 was initially shown to be up-regulated at the 
RNA level in peritoneal macrophages treated with LPS (  3  ). 
In experimental autoimmune encephalomyelitis, a murine 
model of multiple sclerosis, CCRL2 RNA is expressed in the 
spinal column early during the onset of disease by astrocytes, 
microglia, and infi  ltrating macrophages (  4  ). Astrocytes and 
microglia also up-regulate mCCRL2 in response to LPS (  5  ). 
In a model of ovalbumin-induced airway infl  ammation, infi  ltrat-
ing lung macrophages express CCRL2 RNA after ovalbumin 
challenge, whereas the bronchial epithelium is constitutively 
positive for expression (  6  ). By mAb staining, huCCRL2 is 
expressed by circulating human T cells, neutrophils, mono-
cytes, CD34  +  BM precursors, and monocyte-derived macro-
phages and DCs and is generally up-regulated upon activation 
of such cells (  7  ). HuCCRL2 is also expressed on synovial 
fl  uid neutrophils (from rheumatoid arthritis patients) and is 
up-regulated on freshly isolated blood neutrophils treated 
with LPS or TNF      (  8  ). Although there is a study indicating 
that CCR2 ligands such as CCL2 act as functional ligands for 
CCRL2 (  9  ), this fi  nding remains controversial (  8  ; for review 
see reference   10  ). 
  Several atypical serpentine GPCRs that are homologous 
to chemoattractant receptors bind to chemoattractants but 
fail to transduce intracellular signals through heterotrimeric G 
proteins and/or support cell migration. This functionally de-
fi  ned receptor subfamily is currently thought to be comprised 
of three members: D6, DARC (Duff  y antigen receptor for 
chemokines), and CCX-CKR (ChemoCentryx chemokine 
receptor) (for review see references   10, 11  ). These receptors are 
also referred to as professional chemokine   “  interceptors,  ”   a 
name which refl  ects their ability to effi   ciently internalize 
bound ligand (  12  ). These receptors also lack the consensus 
DRYLAIV-related sequence present in the second intra-
cellular loop domain of most chemokine receptors, possibly 
accounting for their inability to transduce classical intracellu-
lar signals (the sequence is DKYLEIV in D6, LGHRLGA in 
DARC, and DRYWAIT in CCX-CKR). Identifying ligands 
for   “  silent  ”   or nonsignaling orphan receptors has proven to 
be particularly challenging because the assays employed in 
most GPCR ligand screens generally depend on functional 
responses, such as intracellular calcium mobilization, cell mi-
gration, or transcriptional activation. 
  D6 is expressed by lymphatic endothelium and by some 
leukocytes and binds proinfl  ammatory CC chemokines. It is 
constitutively internalized (independent of chemokine binding) 
and can rapidly degrade large quantities of chemokines (  13  ). 
DARC is expressed by vascular endothelium and is present 
on RBCs. It binds mostly proinfl  ammatory chemokines (both 
CC and CXC types), and its expression on RBCs can buff  er 
levels of circulating chemokines (  14, 15  ). DARC-bound 
chemokines on erythrocytes are not presented or transferred JEM VOL. 205, September 29, 2008 
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mast cells, and the expression is surprisingly selective for mast 
cells in the absence of pathological stimuli. 
  Mast cells derived from BM progenitors in vitro (BMC-
MCs) up-regulated expression of mCCRL2 over time in cul-
ture. Early mast cell progenitors were negative for mCCRL2, 
but after   >  2 mo in culture, the cells uniformly expressed de-
tectable levels of mCCRL2, albeit with lower levels than 
those on peritoneal mast cells in vivo (  Fig. 1 D  ). We con-
fi  rmed RNA expression of mCCRL2 in peritoneal mast cells 
by real-time quantitative RT-PCR (  Fig. 1 E  ). 
  CCRL2 and mast cell phenotype and function 
  We evaluated numbers of mast cells in CCRL2 KO mice 
in vivo, as well as certain basic functions of CCRL2 KO 
BMCMC in vitro. Our anti-mCCRL2 mAbs failed to stain 
peritoneal mast cells from CCRL2 KO mice, confi  rming the 
genetic ablation of the gene (  Fig. 2 A  ).   The mice are fertile, 
reproduce with the expected Mendelian distribution of KO/
heterozygotes/WT and male/female ratios, and display no 
diff  erences in basal mast cell numbers in the ear skin or in 
mesenteric windows (  Fig. 2 B  ). 
  CCRL2 KO and WT BMCMCs expressed similar levels 
of c-kit (CD117) and Fc     RI (unpublished data). BMCMCs 
from WT or mCCRL2 KO mice also displayed similar che-
motactic responses to stem cell factor (SCF), indicating no 
inherent diff  erences in cell migration (  Fig. 3 A  ), similar de-
granulation responses to antigen-mediated IgE/Fc     RI cross-
linking as assessed by      -hexosaminidase release (  Fig. 3 B  ), and 
similar activation-dependent secretion of cytokines TNF      
of mCCRL2 KO mouse origin exhibited responses to IgE 
and specifi  c antigen-mediated cross-linking of Fc     RI that were 
statistically indistinguishable from those of WT BMCMCs. 
In IgE-dependent PCA reactions in vivo, a model of IgE-
mediated local anaphylaxis, mast cell  –  expressed CCRL2 was 
not required for the development of cutaneous infl  ammatory 
responses in mice sensitized with a high dose of antigen-specifi  c 
IgE. However, mast cell  –  expressed CCRL2 was required for 
the development of optimal cutaneous tissue swelling and 
leukocyte infi  ltrates in mice sensitized with a low dose of anti-
gen-specifi  c IgE. 
  To investigate the mechanism by which CCRL2 may 
contribute to infl  ammation, we sought to identify potential 
CCRL2 ligands. In experiments based on binding rather 
than functional output, we identifi  ed chemerin as a novel non-
signaling protein ligand for both human and mouse recep-
tors. As opposed to chemokine interceptors that serve as a 
sink for chemokines upon their ligand-induced internaliza-
tion, chemerin is not rapidly internalized by CCRL2. Rather, 
CCRL2 concentrates the chemoattractant and increases local 
chemerin concentrations available to interact with CMKLR1. 
We propose that CCRL2 is a novel attractant receptor, serv-
ing to focus chemerin localization in vivo and contribute to 
CMKLR1-mediated processes that, in turn, regulate path-
ways leading to increased vascular permeability, tissue swell-
ing, and leukocyte recruitment. 
    RESULTS   
  mCCRL2-specifi  c mAbs selectively stain mouse mast cells 
  We generated monoclonal antibodies BZ5B8 and BZ2E3 
(IgG  2a       ) with reactivity to the extracellular amino-terminal 
domain of mCCRL2 (  Fig. 1 A  ).   The antibodies were specifi  c 
to mCCRL2-hemagglutinin (HA)/L1.2 transfectants, display-
ing no cross-reactivity with other GPCR/L1.2 transfectants 
tested (mCMKLR1, huCMKLR1, mCRTH2, huCCRL2, or 
mCCR10). Reactivity with CXCR1  –  6 and CCR1  –  10 was 
excluded by lack of staining of blood cell subsets or cultured 
mouse cells known to express these receptors (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20080300/DC1; 
and not depicted). In agreement with published RNA ex-
pression data (  3  ), peritoneal macrophages treated with LPS 
up-regulated mCCRL2 protein expression. Expression of 
mCCRL2 was also up-regulated in such cells by treatment 
with TNF     , IFN-     , or poly:IC (Fig. S2 A). 
  Freshly isolated mouse blood T cells, B cells, NK cells, 
BM neutrophils, and resting peritoneal macrophages were all 
negative for mCCRL2 expression (Fig. S1 A). A small popu-
lation of highly granular (SSC  high  ) F4/80         c-kit  +   leukocytes 
in the peritoneal cavity, however, uniformly stained for mC-
CRL2 (  Fig. 1 B  ). These cells also expressed the high-affi   nity 
IgE Fc receptor Fc     RI (unpublished data). On staining with 
Wright-Giemsa stain, sorted F4/80        CCRL2  +   cells displayed 
intense metachromatic staining of abundant cytoplasmic gran-
ules, as did mast cells sorted as F4/80         c-kit  +   cells (  Fig. 1 C  ). 
Thus, both traditional morphological and immunophenotypic 
analyses indicate that mCCRL2 is constitutively expressed by 
    Figure 1.         Mast cells express mCCRL2.   (A) Generation of anti-mCCRL2 
specifi  c mAbs. Unlabeled mCCRL2/L1.2 transfectants were mixed 1:1 with 
CMFDA-labeled CCR10/L1.2 transfectants and used to identify mCCRL2-
specifi  c mAbs by fl  ow cytometry. (B) Freshly isolated peritoneal leukocytes 
were harvested and mCCRL2 expression was evaluated on SSC  high   F4/80       
c-kit  +   mast cells. (C) F4/80         mCCRL2 +   and  F4/80        c-kit +   peritoneal cells 
were sorted, harvested by cytospin, and stained by Wright-Giemsa. Cells 
were examined by light microscope using a 40  ×   objective. Bars, 10   μ  m. 
(D) BMCMCs were generated and stained for mCCRL2 reactivity. (E) The rela-
tive RNA expression of mCCRL2 was assessed in mast cells by real-time 
quantitative PCR. The expression data were normalized to   Cyclophilin A  
and displayed relative to   mCCRL2   expression in the spleen (set = 1). Each 
bar represents the mean   ±   SD of triplicate wells. ND, not detectable. One 
representative dataset of the at least three experiments, each of which 
gave similar results, is shown for each part of this fi   gure.   2210 ROLE OF CCRL2 IN I  G  E-DEPENDENT INFLAMMATION   | Zabel et al. 
with 150 ng/ear DNP-specifi  c IgE and challenged with anti-
gen (2,4-DNP-conjugated human serum albumin [DNP-
HSA]) i.v. developed strong local infl  ammatory responses, 
with no signifi  cant diff  erence in the tissue swelling observed 
in WT versus CCRL2 KO mice (82   ±   9 vs. 91   ±   9   ×   10       2   
mm of swelling at 30 min after antigen challenge, respectively; 
P   >   0.05, Student  ’  s   t   test; Fig. S4 A, available at http://www
.jem.org/cgi/content/full/jem.20080300/DC1). However, 
when the sensitizing dose of DNP-specifi  c IgE was reduced 
to 50 ng/ear, the PCA reactions in CCRL2 KO mice were 
signifi  cantly impaired compared with those in WT mice 
(42.2   ±   2.8 vs. 24.9   ±   2.7   ×   10       2   mm of swelling at 30 min 
after antigen challenge, respectively; P   <   0.005, Student  ’  s   t   
test;   Fig. 4 A  ).   
  To assess the extent to which mCCRL2 expression spe-
cifi  cally on mast cells was critical for the defect in IgE-depen-
dent PCA observed in mCCRL2 KO mice, we engrafted 
mast cell  –  defi  cient   Kit  W-sh/Wsh     mice intradermally in the ear 
pinnae with either WT or mCCRL2 KO BMCMCs. 6  –  8 wk 
later, the animals were subjected to IgE-dependent PCA. 
Such mast cell engraftment of mast cell  –  defi  cient   Kit  W-sh/Wsh     
or   Kit  W/W-v     mice is routinely used to identify the roles of mast 
cells in biological responses in vivo (  29  ). There was no diff  er-
ence in the extent of PCA-associated ear swelling between 
  Kit  W-sh/Wsh     mice that had been engrafted with WT versus 
and IL-6 (  Fig. 3 C  ).   We recently showed that antigen-mediated 
IgE/Fc     RI cross-linking up-regulated expression of several 
costimulatory molecules on BMCMCs (  31  ); however, we 
did not detect any CCRL2-dependent diff  erences in CD137 
(4-1BB) or CD153 (CD30L) induction (  Fig. 3 D  ). BMC-
MCs stimulated by antigen-mediated IgE/Fc     RI cross-link-
ing also can enhance T cell proliferation (  31, 32  ). Although 
naive T cells proliferated markedly in response to treatment 
with anti-CD3 and coincubation with mitomycin C  –  treated 
antigen-specifi  c IgE-stimulated BMCMCs, there were no 
CCRL2-dependent diff  erences in the ability of BMCMCs 
to enhance T cell proliferation (  Fig. 3 E  ) or T cell secretion 
of IFN-      or IL-17 (not depicted) in the conditions tested. 
Thus, the presence of absence of CCRL2 on BMCMCs 
did not signifi  cantly infl  uence the basic mast cell functions 
tested here. 
  Mast cell  –  expressed CCRL2 is required for optimal 
induction of IgE-dependent PCA 
  To search for potential contributions of CCRL2 to patho-
physiologic responses in vivo, we next examined certain in-
fl  ammatory conditions that are known to involve mast cells. 
Mast cells are required for optimal expression of the T cell  –
  mediated contact hypersensitivity (CHS) induced by a proto-
col using FITC but not that induced by other protocols using 
DNFB (2,4-dinitro-1-fl  uorobenzene)  (  33, 34  ). However, 
CCRL2 was largely dispensable for the tissue swelling asso-
ciated with FITC-triggered CHS, as both WT and CCRL2 
KO mice developed statistically indistinguishable responses 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20080300/DC1). 
  We next examined a mast cell  –  dependent model of atopic 
allergy, the IgE-dependent PCA reaction. Animals sensitized 
    Figure 2.           mCCRL2   KO mice.   (A)   mCCRL2   KO mice are defi  cient in 
CCRL2 protein expression. Freshly isolated peritoneal leukocytes were 
harvested and mCCRL2 expression was evaluated on SSC  high F4/80        ckit +  
mast cells. A representative histogram plot of the at least three inde-
pendent experiments performed, each of which gave similar results, is 
shown. (B) Enumeration of ear skin and mesenteric mast cells in WT 
and KO mice. Ear skin: KO (  n   = 9), WT,het (  n   = 4,1), 4 sections/mouse. 
Mesenteric window: KO (  n   = 18), WT,het (  n   = 9,2). The mean   ±   SEM 
is displayed.     
    Figure 3.         BMCMCs from   mCCRL2   KO and WT mice display similar 
functional responses in vitro.   (A) In vitro transwell chemotaxis to SCF. 
Four populations of BMCMCs were tested, with duplicate wells for each 
genotype. The mean   ±   SEM is displayed. (B  –  D) BMCMCs were sensitized 
with DNP-specifi  c IgE and then activated by addition of DNP-HSA. The 
following parameters were measured: Degranulation (as quantifi  ed by 
     -hexosaminidase release; B), TNF      and IL-6 secretion (C), and up-
regulation of costimulatory molecules CD137 and CD153 (D). (E) BMCMC-
stimulated T cell proliferation. Naive T cells were incubated as indicated 
with anti-CD3 and cocultured with mitomycin C  –  treated BMCMCs from 
WT or CCRL2 KO mice preincubated with or without DNP-specifi  c IgE and 
tested in the presence or absence of DNP-HSA. Cell proliferation was 
measured by tritiated thymidine incorporation. For B, C, and D,   n   = 7 KO, 
  n   = 4 WT, mean   ±   SD. For E, the mean of triplicate measurements   ±   SD is 
shown for a representative dataset of three experiments (each of which 
gave similar results).     JEM VOL. 205, September 29, 2008 
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  However, when the sensitizing dose of DNP-specifi  c IgE 
was reduced to 5 ng/ear, there was a signifi  cant reduction in 
ear swelling responses in mice that had been engrafted with 
mCCRL2 KO BMCMCs compared with those that had been 
engrafted with WT BMCMCs (12.5   ±   1.2 vs. 8.4   ±   0.8   ×   
10       2   mm of swelling at 30 min after antigen challenge, re-
spectively; P   <   0.01, Student  ’  s   t   test;   Fig. 4 B  ). There were no 
signifi  cant diff  erences in the total number of mast cells de-
tected histologically in WT versus CCRL2 KO BMCMC-
engrafted ears, thus ruling out any CCRL2-dependent eff  ects 
on mast cell engraftment effi   ciency (  Fig. 4 C  ). However, at 
6 h after antigen challenge, IgE-dependent PCA reactions in 
ears that had been engrafted with CCRL2 KO mast cells con-
tained     50% fewer leukocytes (predominantly neutrophils 
and mononuclear cells) than did reactions in ears that had 
been engrafted with WT mast cells (P   <   0.03, Mann Whitney 
  U   test;   Fig. 4 D   and   Fig. 5  ).   IgE-dependent PCA reactions 
were associated with a marked reduction in the numbers of 
dermal mast cells that could be identifi  ed in histological sec-
tions of these sites based on the staining of the cells  ’   cytoplas-
mic granules (  Fig. 4 C  ), an eff  ect which most likely refl  ected 
extensive mast cell degranulation at these sites (  35, 36  ). 
  We conclude that although mast cell  –  expressed mCCRL2 
is not required for the development of IgE-dependent PCA 
reactions in vivo, mast cell expression of CCRL2 can signifi  -
cantly enhance the local tissue swelling and leukocyte infi  l-
trates associated with such reactions in mice that have been 
sensitized with relatively low amounts of antigen-specifi  c IgE. 
  CCRL2 binds chemerin 
  To investigate possible functional roles for CCRL2, we set 
out to validate/identify CCRL2 ligands. It was reported that 
mCCRL2 KO BMCMCs when the animals were sensitized 
with 50 ng/ear DNP-specifi  c IgE and challenged with i.v. 
antigen (19.5   ±   3.6 vs. 19.9   ±   2.6   ×   10       2   mm of swelling at 
30 min after antigen challenge, respectively; P   >   0.05, Stu-
dent  ’  s   t   test; Fig. S4 B). Nor was there a signifi  cant diff  erence 
in the numbers of leukocytes infi  ltrating the dermis at these 
sites at 6 h after antigen challenge (Figs. S4 C and S5). 
    Figure 4.         Mast cell  –  expressed mCCRL2 is required for maximal 
tissue swelling and numbers of dermal leukocytes in PCA.   (A) WT or 
CCLR2 KO mice were sensitized by injection of 50 ng of anti-DNP IgE into 
left ear skin (with vehicle injection into right ear skin as the control). The 
mice were challenged by i.v. injection of DNP-HSA (200   μ  g/mouse) the 
next day, and ear swelling was measured at the indicated time points 
(mean   ±   SEM;   n   = 3 experiments with a total of 21 KO and 16 WT mice 
per group). *, P   <   0.005 by ANOVA comparing swelling in WT vs. KO ears 
sensitized with antigen-specifi  c IgE. (B  –  D) The ears of mast cell  –  defi  cient 
  Kit  W-sh/Wsh    mice were engrafted with BMCMCs from either WT or mCCRL2 
KO mice. 6  –  8 wk later, the mice were sensitized (5 ng IgE/left ear, with 
vehicle into the right ear as the control), challenged with specifi  c antigen 
(200   μ  g DNP-HSA i.v.), and assessed for tissue swelling (B), as described in 
A, and for numbers of mast cells (C) or leukocytes (D) per millimeters 
squared of dermis. Data are shown as mean   ±   SEM,   n   = 3 experiments, 
with 15 total mice per group in B, and the numbers of mice sampled for 
histological data are shown in C and D. *, P   <   0.001 by ANOVA comparing 
swelling in mCCRL2 KO BMCMC- vs. WT BMCMC-engrafted ears sensi-
tized with antigen-specifi  c IgE. (C) Enumeration of mast cells present in 
the dermis of ear skin in engrafted animals from B after elicitation of PCA 
(IgE) or in vehicle-injected control (vehicle) ears. **, P   <   0.005 by Student  ’  s 
  t   test versus values for the vehicle-injected ears in the corresponding WT 
BMCMC- or KO BMCMC-engrafted   Kit  W-sh/Wsh    mice. (D) Numbers of leuko-
cytes per millimeters squared of dermis, assessed in formalin-fi  xed paraf-
fi  n-embedded hematoxylin and eosin  –  stained sections of mice from 
B and C. ***, P   <   0.0001 by the Mann Whitney   U   test versus corresponding 
values for the vehicle-injected ears in WT BMCMC- or KO BMCMC-en-
grafted   Kit  W-sh/Wsh    mice. The numbers over the bars for vehicle-injected 
mice are the mean values.     
    Figure 5.         Histological features of IgE-dependent PCA reactions in 
WT BMCMC- versus KO BMCMC-engrafted   Kit  W-sh/Wsh     mice.   Histo-
logical sections of ear skin from WT BMCMC-engrafted   Kit  W-sh/Wsh    mice 
(A  –  C) and KO BMCMC-engrafted   Kit  W-sh/Wsh    mice (D  –  F) from the same 
group shown in   Fig. 4 D   analyzed 6 h after i.v. injection of DNP-HSA show 
no evidence of infl  ammation in vehicle-sensitized ears (A and D), but 
evidence of tissue swelling and increased numbers of leukocytes in DNP-
specifi  c IgE-sensitized ears (B, C, E, and F). Enlargements of the boxed 
regions in B and E are shown in C and F, respectively. The infl  ammatory 
infi  ltrate consists predominantly of polymorphonuclear leukocytes (some 
indicated by arrowheads in C and F) and occasional mononuclear cells 
(indicated by an arrow in C). Bars, 50   μ  m.     2212 ROLE OF CCRL2 IN I  G  E-DEPENDENT INFLAMMATION   | Zabel et al. 
mCCRL2/HEK293 transfectants respond functionally to 
CCR2 ligands CCL2, CCL5, CCL7, and CCL8 via intra-
cellular calcium mobilization and transwell chemotaxis (  9  ), 
although this conclusion is controversial (  8  ; for review see 
reference   10  ). These chemokines did not induce migration 
of mCCRL2/L1.2 transfectants in our in vitro transwell che-
motaxis assays (Fig. S6, available at http://www.jem.org/cgi/
content/full/jem.20080300/DC1). We also tested a panel of 
known chemoattractants (CCL11, CCL17, CCL22, CCL25, 
CCL27, CCL28, CXCL9, and CXCL13), as well as protein 
extracts from homogenized mouse tissues (lungs, kidney, liver, 
brain, and spleen), and found that none stimulated mCCRL2-
dependent chemotaxis in our in vitro transwell chemotaxis 
assays (unpublished data). Given the aberrant DRYLAIV 
motif that is present in mouse and human CCRL2, we and 
others postulated that mCCRL2 may act as a silent receptor 
(for review see reference   10  ), which is capable of binding 
chemoattractants but incapable of transducing signals via clas-
sical second messengers. That hypothesis is consistent with 
the negative results obtained in our eff  orts to induce chemo-
taxis of mCCRL2/L1.2 transfectants in our in vitro transwell 
chemotaxis assays. 
  Although we failed to identify evidence of signaling ef-
fects of any of the tested chemoattractants, we were able to 
identify a high-affi   nity ligand for the receptor: in indepen-
dent studies in which we were using our anti-CCRL2 mAbs 
as controls for staining, we serendipitously discovered that 
chemerin, a protein ligand for signaling receptor CMKLR1 
(for review see reference   28  ), inhibited the binding of mC-
CRL2-specifi  c mAbs to mouse peritoneal mast cells. In   Fig. 
6 A  , we illustrate the potent ability of chemerin to inhibit 
anti-CCRL2 staining of mouse peritoneal mast cells.   Increas-
ing concentrations of chemerin blocked the binding of anti-
mCCRL2 BZ5B8 (  Fig. 6 A  ) and BZ2E3 (not depicted) in a 
dose-dependent manner (EC  50   = 21 nM). The eff  ect was 
specifi  c to anti-mCCRL2:mCCRL2 interactions because bind-
ing of IgE to FcR     I was unaff  ected by 1,000 nM chemerin 
(  Fig. 6 A  ), and 1,000 nM CCL2 had no eff  ect on CCRL2 
staining (  Fig. 6 A  ). 
  To confi  rm the identifi  cation of CCRL2 as a chemerin 
receptor, we performed radioligand binding studies using 
  iodinated chemerin. Cells were incubated with a fi  xed con-
centration of radiolabeled human chemerin plus increasing 
concentrations of unlabeled chemerin. Chemerin bound spe-
cifi  cally to mCCRL2-HA/L1.2 transfectants (EC  50   = 1.6 nM; 
  Fig. 6 B  ), but no binding was detected to untransfected or 
mCRTH2-HA  –  transfected cells (a prostaglandin D  2   binding 
chemoattractant receptor; not depicted). Furthermore, de-
spite being the most divergent mouse-to-man orthologues 
in the chemoattractant receptor subfamily, huCCRL2 also 
bound specifi  cally to chemerin (EC  50   = 0.2 nM;   Fig. 6 B  ). The 
binding affi   nity of chemerin for CCRL2 was similar to, if not 
slightly better than, chemerin binding to the fi  rst identifi  ed 
chemerin receptor, mCMKLR1 (EC  50   = 3.1 nM;   Fig. 6 B  ). In 
saturation binding studies, chemerin bound to mCCRL2 at a 
single binding site with a calculated kD of 1.6 nM (  Fig. 6 C  ). 
    Figure 6.         CCRL2 binds chemerin.   (A) Chemerin blocks anti-CCRL2 
mAb binding. Various concentrations of human chemerin or CCL2 were 
incubated with total peritoneal mast cells on ice for 5 min, followed by 
incubation with CCRL2-specifi  c mAb BZ2E3 or anti-IgE and detected with 
secondary anti  –  rat PE or anti  –  mouse IgE PE. (B and C) Radiolabeled 
chemerin binding. (B) Displacement of iodinated chemerin (residues 
21  –  148) binding to mCMKLR1, huCCRL2, and mCCRL2 by full-length 
chemerin. (C) Saturation binding of   125 I-chemerin 21-148   to  mCCRL2-trans-
fected cells. (D) Immunofl  uorescence-based chemerin binding. Various 
concentrations of untagged serum form chemerin were incubated with 
mCCRL2-HA, huCCRL2-HA, mCRTH2-HA, or mCMKLR1-HA L1.2 transfec-
tants in the presence of 10 nM His  8  -tagged serum form chemerin. Sam-
ples were incubated on ice for 30 min. Secondary anti-His  6   PE was added 
to detect levels of bound His  8  -tagged chemerin, and mean fl  uorescence 
intensity values are displayed. Mean fl  uorescence intensity   ±   range of 
duplicate staining wells are shown. (E) Mast cell binding. 1,000 nM of 
untagged chemerin isoforms were incubated with total peritoneal cells 
from either WT or CCRL2 KO mice in the presence or absence of 10 nM 
His  8  -tagged chemerin isoforms. Secondary anti-His  6   PE was added to 
detect levels of bound His  8  -tagged chemerin. SSC  high   F4/80        c-kit +   mast 
cells were analyzed. For B and C, the mean of quadruplicate wells   ±  SD is 
shown for individual experiments. A representative dataset of the three 
(for B, D, and E) or two experiments (for A and C) performed, each of 
which gave similar results, is shown.     JEM VOL. 205, September 29, 2008 
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was reported that CCL2 triggered intracellular calcium mo-
bilization in CCRL2/HEK293 transfectants, in our experi-
ments neither CCL2 nor chemerin functioned as agonists 
for CCRL2 in the HEK293 background, either alone or in 
combination (Fig. S9, available at http://www.jem.org/cgi/
content/full/jem.20080300/DC1). 
  Because GPCR function can require cell type  –  specifi  c 
cofactors, we wanted to determine whether CCRL2 could 
mediate chemerin signaling when expressed physiologically 
on mouse peritoneal mast cells. Chemerin did not trigger 
intracellular calcium mobilization in freshly isolated mouse 
peritoneal mast cells, although these cells responded to ATP 
(via purinoreceptors [reference   37  ]), indicating their compe-
tence in this assay (  Fig. 7 B  ). Furthermore, neither human nor 
mouse CCRL2-HA/L1.2 transfectants migrated to a range of 
doses of chemerin in in vitro transwell chemotaxis experi-
ments (  Fig. 7 C  ). Freshly isolated mouse peritoneal mast cells 
also failed to migrate to chemerin (  Fig. 7 D  ). In comparison, 
chemerin triggered a robust dose-dependent migratory response 
in mCMKLR1-HA/L1.2 cells (  Fig. 7 C  ). Mouse and human 
CCRL2/L1.2 cells migrated to CXCL12 and CCL19 (via 
endogenously expressed CXCR4 and CCR7, respectively), 
  We developed an immunofl  uorescence-based chemerin-
binding assay to evaluate chemerin binding by fl  ow cytometry. 
Cells were incubated with a fi  xed concentration of C-terminal 
His  8  -tagged serum form human chemerin plus increasing con-
centrations of untagged chemerin, and anti-His  6   PE was used 
to detect binding. In this assay, chemerin bound specifi  cally 
to mCCRL2-HA (EC  50   = 45 nM) and huCCRL2 (EC  50   = 
7 nM) L1.2 transfectants (  Fig. 6 D  ). Chemerin binding to 
CCRL2 was not aff  ected by a variety of other chemoattrac-
tants (Fig. S7, available at http://www.jem.org/cgi/content/
full/jem.20080300/DC1), and mCRTH2-HA/L1.2 transfec-
tants did not bind to chemerin (  Fig. 6 D  ), demonstrating speci-
fi  city for chemerin  –  CCRL2 interactions. Interestingly, we were 
unable to detect chemerin binding to mCMKLR1-HA/L1.2 
transfectants in the immunofl  uorescence chemerin binding as-
say (  Fig. 6 D  ). This may refl  ect inhibition of binding by 
the C-terminal His  8   tag (which would be analogous to the 
inhibitory activity of the carboxyl-terminal residues in the 
chemerin proform) or, potentially, inaccessibility of the His  8   
epitope to the detection mAbs when His  8  -tagged chemerin is 
bound to CMKLR1. 
  In radioligand binding studies, the His  8   tag had little eff  ect 
on the potency of chemerin binding to mCCRL2 (EC  50   = 0.8 
nM); however, His  8  -tagged chemerin bound with 10-fold less 
potency to mCMKLR1 (EC  50   = 26.3 nM; Fig. S8 A, available 
at http://www.jem.org/cgi/content/full/jem.20080300/DC1). 
The bioactive 9-mer carboxyl-terminal chemerin peptide (res-
idues 149  –  157, YFPGQFAFS) was 10-fold less potent (EC  50   = 
26.2 nM; see   Fig. 8 A  ) than chemerin protein in binding 
to CMKLR1. In CCRL2 binding, however, the bioactive 
chemerin peptide was an ineffi   cient competitor (EC  50   could 
not be determined, Fig. S8 B). Thus, the data indicate distinct 
binding modes for chemerin and CCRL2 versus chemerin and 
CMKLR1. The carboxyl-terminal domain of chemerin that is 
critical for binding to CMKLR1 is relatively uninvolved and 
unencumbered when chemerin is bound to CCRL2. 
  Freshly isolated mouse peritoneal mast cells also bound to 
chemerin (  Fig. 6 E  ), and there was no obvious preference for 
binding of the proform versus the active serum form (this was 
also observed in radioligand binding studies using L1.2 trans-
fectants; not depicted). Moreover, mouse peritoneal mast cells 
bound both human and mouse chemerin (  Fig. 6 E  ). Finally, 
peritoneal mast cells from mCCRL2 KO mice did not bind to 
chemerin, further confi  rming the role of CCRL2 in the bind-
ing of chemerin to such mast cells (  Fig. 6 E  ). 
  CCRL2 does not support chemerin-driven 
signal transduction 
  Despite high-affi   nity binding to mCCRL2, chemerin failed to 
trigger intracellular calcium mobilization in mCCRL2/L1.2 
transfectants (  Fig. 7 A  ).   Chemerin triggered a robust calcium fl  ux 
in cells expressing the chemerin signaling receptor mCMKLR1, 
confi  rming its activity (  Fig. 7 A  ). mCCRL2-HA/L1.2 trans-
fectants responded to CXCL12 (via endogenous CXCR4), 
indicating their competence for demonstrating calcium mo-
bilization in this assay (  Fig. 7 A  ). Furthermore, although it 
    Figure 7.         Chemerin-CCRL2 binding does not trigger intracellular 
calcium mobilization or chemotaxis.   (A) mCCRL2 and mCMKLR1 L1.2 
transfectants were loaded with Fluo-4, treated with chemerin and/or 
CXCL12 at the indicated times, and examined for intracellular calcium 
mobilization. (B) Mouse peritoneal mast cells were enriched by NycoPrep 
density centrifugation, loaded with Fura-2 and Fluo-4, and assayed for 
calcium mobilization. 1,000 nM chemerin and 100 nM ATP were added as 
indicated. (C) mCCRL2-HA, huCCRL2-HA, and mCMKLR1-HA L1.2 trans-
fectants were tested for transwell chemotaxis to various concentrations 
of chemerin. The mean   ±   range of duplicate wells is shown. (D) Mouse 
peritoneal mast cells were assayed for in vitro chemotaxis to various con-
centrations of SCF and chemerin. Mast cells were identifi  ed by gating on 
SSC  high   CD11b        c-kit +   cells. The mean   ±   SD of triplicate wells is shown for 
an individual experiment. *, P   <   0.01 by Student  ’  s   t  -test comparing migra-
tion to 0.05 nM SCF versus (     ) no chem. A representative dataset of the 
three experiments performed, each of which gave similar results, is shown 
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and primary mouse peritoneal mast cells migrated to stem cell 
factor (SCF), indicating their ability to demonstrate chemo-
taxis is this assay (  Fig. 7, C and D  ). Furthermore, CCL2 and 
chemerin did not synergize with each other to induce a func-
tional migratory response in mCCRL2/L1.2 transfectants in 
in vitro transwell migration assays (unpublished data). 
  CCRL2 does not internalize chemerin 
  Our data place CCRL2 in a class of atypical receptors that 
include D6, DARC, and CCX-CKR, all of which bind to 
chemoattractants but do not support classical ligand-driven 
signal transduction (for review see reference   11  ). These other 
receptors have recently been termed professional   “  chemo-
kine interceptors  ”   because they internalize and either degrade 
and/or transcytose chemokines (for review see [  10,11  ]) (  12  ). 
To ask whether CCRL2 might have interceptor activity, we 
assessed the internalization of CCRL2, and of CMKLR1 for 
comparison, in response to ligand binding. mCMKLR1-HA 
internalized rapidly (within 15 min) in response to 100 nM 
chemerin, and this internalization was inhibited by incuba-
tion on ice and in the presence of sodium azide (  Fig. 8 A  ), 
confi  rming that the eff  ect is an active process (not caused 
by chemerin-mediated displacement of the anti-HA mAb).   
In contrast, under the same conditions, CCRL2 failed to in-
ternalize. Neither mouse nor human CCRL2, expressed on 
L1.2 transfectants, underwent ligand-induced internalization 
(  Fig. 8 A  ). Even prolonged incubation with chemerin (2 h at 
37  °  C) failed to signifi  cantly reduce surface receptor levels 
(unpublished data). 
  We also asked whether CCRL2 might undergo constitu-
tive ligand-independent endocytosis, as has been observed 
with D6 (  13  ). Cell surface mCCRL2-HA and mCMKLR1-
HA were stained with primary anti-HA mAb on ice, washed, 
and then shifted to 37  °  C for various times to permit receptor 
internalization. The cells were then stained with a secondary 
antibody to detect remaining surface anti-HA mAb. At the 
15-min time point, neither mCCRL2 nor mCMKLR1 had 
undergone substantial ligand-independent endocytosis, which 
is similar to CCX-CKR (  19  ) and in contrast to D6 (  13  ). By 
60 min there was a noticeable reduction in staining intensity 
for both human and mouse receptors, suggesting low-level 
constitutive endocytosis, receptor turnover, and/or antibody 
release (  Fig. 8 B  ). 
  Given that chemerin does not trigger mCCRL2 inter-
nalization, it is unlikely that chemerin itself is internalized 
in substantial amounts in CCRL2  +  cells (in the absence of 
CMKLR1). To confi  rm this directly, we loaded mCCRL2-
HA/L1.2 cells with His  8  -tagged serum form chemerin and 
anti-His  6   PE on ice and then shifted the cells to 37  °  C to per-
mit internalization. At the indicated time points, the cells 
were washed with either PBS or a high-salt acid wash buff  er 
that strips bound chemerin from the surface of the cell (  Fig. 
8 C  , zero time point). In contrast to D6 and CCX-CKR, 
where   >  70% of cell-associated CCL3 (  13  ) and 100% of cell-
associated CCL19 (  19  ) became resistant to acid wash within 
5 min, respectively, there was essentially no acid-resistant 
    Figure 8.         CCRL2 can increase local chemerin concentrations.  
(A) Chemerin does not trigger CCRL2 receptor internalization. mCCRL2-HA, 
huCCRL2-HA, and mCMKLR1-HA L1.2 transfectants were stained with 
anti-HA mAb and then incubated with or without 100 nM chemerin for 
15 min at the indicated temperatures. (B) mCCRL2 is not rapidly constitu-
tively internalized. mCCRL2-HA and mCMKLR1-HA L1.2 transfectants 
were incubated with primary anti-HA mAb, incubated for the indicated 
times at 37  °  C, and then stained with secondary anti-mIgG1 PE. mCMKLR1 
cells incubated with 100 nM of serum-form chemerin served as a positive 
control. (C and D) Chemerin is not rapidly internalized. mCCRL2-HA L1.2 
transfectants (C) or total peritoneal exudate cells (D) were incubated with 
10 nM His  8  -tagged serum form chemerin and anti-His  6   PE for 1 h on ice 
and then shifted to 37  °  C. At the indicated time points, the cells were then 
washed with either PBS or acid wash buffer. Mast cells were identifi  ed by 
gating on SSC  high   F4/80        c-kit +   cells in D. (E) CCRL2 can sequester 
chemerin from solution. 2 nM of serum-form chemerin was incubated 
with the indicated transfectant lines (or media alone) for 15 min at 37  °  C. 
The cells were removed by centrifugation, and the conditioned media was 
tested in transwell chemotaxis using mCMKLR1HA/L1.2 responder cells. 
The mean   ±   SD of triplicate wells for an individual experiment is shown. 
(F) CCRL2 can increase local concentrations of bioactive chemerin. mC-
CRL2-HA or empty vector pcDNA3 L1.2 transfectants were preloaded with 
1,000 nM of serum-form chemerin and washed with PBS. mCMKLR1/L1.2 
loaded with Fluo-4 served as responder cells. The intracellular calcium 
mobilization in the responder cells was measured over time as loaded 
cells or purifi  ed chemoattractant was added. Note that different scales 
are used on either side of the broken-axis indicator. A representative da-
taset of the three experiments performed, each of which gave similar 
results, is shown for all parts of this fi   gure.   JEM VOL. 205, September 29, 2008 
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cells (  Fig. 9  ).   In its role as a specialized molecule for concen-
trating extracellular chemerin, CCRL2 may operate akin to 
glycosaminoglycans, which are thought to bind, concentrate, 
and present chemokines to leukocytes and facilitate their 
chemotaxis (  38  ). 
  In experimental IgE-dependent PCA, a simple in vivo 
model of an IgE- and mast cell  –  dependent acute allergic re-
action, CCLR2-defi  cient mice expressed WT levels of tissue 
swelling when the mice were sensitized with one dose of 
  antigen-specifi  c IgE but exhibited signifi  cantly reduced tissue 
swelling associated with PCA reactions elicited in mice sensi-
tized with one third less antigen-specifi  c IgE. This clearly 
shows that mast cell expression of CCLR2 is not required for 
elicitation of IgE-dependent PCA but may substantially en-
hance reactions elicited under conditions where IgE may be 
limiting. PCA has been widely used to study factors involved 
in mast cell responses in vivo (  39, 40  ). In our previous stud-
ies, we showed that pro-chemerin is rapidly activated by ex-
tracellular serine proteases such as secreted mast cell tryptase 
(  27  ). Thus, the acute nature of the PCA reaction is well suited 
to highlight possible consequences of rapid chemerin conver-
sion in vivo. CCRL2 expression by tissue mast cells may 
serve to coat the cells with the proform of chemerin, which 
would be immediately activated upon mast cell degranulation 
and tryptase release (  27  ). 
  The reason why the tissue swelling associated with IgE-
dependent PCA reactions in CCRL2 KO mice was less 
than that observed in WT mice is not yet clear. The largest 
diff  erences in the tissue swelling responses of the WT versus 
KO mice (or in the mast cell  –  defi  cient mice that had been 
cell-associated chemerin at the 5-min time point and very 
little at the 60-min time point (  Fig. 8 C  ). In contrast, there 
was a time-dependent increase in surface-bound chemerin 
(  Fig. 8 C  , PBS wash). Freshly isolated peritoneal mouse mast 
cells also did not internalize chemerin (  Fig. 8 D  , acid wash). 
In contrast to mCCRL2/L1.2 transfectants, however, at the 
60-min time point there was a considerable reduction in sur-
face-bound chemerin (  Fig. 8 D  , PBS wash), suggesting either 
eventual extracellular degradation or chemerin release. Further-
more, mCCRL2-HA/L1.2 transfectants effi   ciently bound 
chemerin from dilute aqueous solutions (  Fig. 8 E  ). Thus, it 
appears that CCRL2 binds and indeed concentrates chemerin 
on the cell surface. 
  Finally, we wanted to assess whether chemerin sequestered 
by mCCRL2  +   cells could trigger a response in mCMKLR1  +   
cells. We loaded empty vector pcDNA3 or mCCRL2-HA 
L1.2 cells with chemerin, washed with PBS, added the loaded 
cells to mCMKLR1/L1.2 responder cells labeled with a cal-
cium-sensitive dye, and assessed intracellular calcium mobili-
zation. Chemerin-loaded mCCRL2-HA/L1.2 cells, but not 
pcDNA3/L1.2 cells, triggered calcium fl  ux in the responder 
cells (  Fig. 8 F  ). Thus, CCRL2 can concentrate bioactive 
chemerin, which then is available for interaction with CMKLR1 
on adjacent cells. 
    DISCUSSION   
  The evolutionary conservation of chemerin binding to CCRL2 
despite divergence in overall sequence between mouse and 
human receptors strongly suggests that the interaction of 
chemerin with CCRL2 is physiologically important. The lack 
of substantial chemerin internalization by CCRL2 disquali-
fi  es the receptor as a professional chemoattractant   interceptor 
and, instead, implicates it as a physiological mediator for the 
concentration and presentation of bioactive chemerin. We 
hypothesize, therefore, that CCRL2 serves a novel role among 
cell surface chemoattractant receptors, regulating the bioavail-
ability of chemerin in vivo to fi  ne-tune immune responses 
mediated via the signaling receptor CMKLR1. Chemerin 
inhibits the binding of mAbs specifi  c to amino-terminal epi-
topes of mCCRL2, implying that chemerin binds directly to 
the amino-terminal domain of the receptor. In this regard, 
it is interesting to note that the fi  rst 16 aa of human and 
mouse CCRL2 share 81% identity, compared with just 17% 
shared identity in the remaining 24 aa of the amino-termi-
nal domain (Fig. S10, available at http://www.jem.org/cgi/
content/full/jem.20080300/DC1). This short conserved 
amino-terminal sequence may therefore embody a critical 
chemerin binding domain. Furthermore, CCRL2 binds to 
chemerin in an orientation that permits antibody access to 
the short C-terminal His  8   tag, suggesting that the critical cell-
signaling carboxyl terminus of chemerin would also be ex-
posed in the untagged form of the protein. Thus, we hypoth-
esize that CCRL2 (e.g. expressed by mast cells and activated 
macrophages) binds to chemerin in vivo and presents the 
cell-signaling carboxyl-terminal domain of the chemoattrac-
tant to CMKLR1  +   cells such as macrophages, pDC, and NK 
    Figure 9.         Proposed model of presentation of chemerin by CCRL2 
to CMKLR1.   (A) Chemerin binds to CCRL2 leaving the C-terminal peptide 
sequence free. The carboxyl-terminal domain of chemerin is critical for 
transducing intracellular signals and interacts directly with CMKLR1. 
CCRL2 may thus allow direct presentation of bound chemerin to adjacent 
CMKLR1-expressing cells. (B) Alternatively, CCRL2 may concentrate the 
ligand for proteolytic processing by activated mast cells or macrophages, 
enhancing the local production of the active form which could then act 
as a chemoattractant after release from the cell surface.     2216 ROLE OF CCRL2 IN I  G  E-DEPENDENT INFLAMMATION   | Zabel et al. 
reservoir of chemerin and to buff  er tissue levels of the attrac-
tant in vivo in the same manner that erythrocyte-expressed 
atypical chemokine receptor DARC can serve as a buff  er 
to maintain chemokine levels in the blood (  14, 15  ). We are 
currently investigating this hypothesis by comparing chemerin 
protein levels in blood and tissue extracts from WT and CCRL2 
KO mice. 
  Transfectant-expressed CCRL2 has been reported to 
bind CCL2 and CCL5, although this result is controversial 
(  9  ). CCL2 did not interfere with anti-mCCRL2 mAb stain-
ing in our studies. In addition, using either the binding con-
ditions published in this paper for chemerin or those published 
by Biber et al. (  9  ) for CCL2, we were unable to confi  rm the 
binding of biotinylated CCL2 to CCRL2/L1.2 transfectants 
(unpublished data). However, it is unclear whether the bioti-
nylated CCL2 reagent available to us is useful for identify-
ing cognate receptor expression because we observed similar 
high background binding of this reagent to T cells in WT and 
CCR2 KO mice. 
  The identifi  cation of natural ligands for silent or nonsig-
naling receptors (such as D6, DARC, and CCX-CKR) has 
lagged behind the deorphaning of signaling receptors. This 
is likely because of an intrinsic bias toward GPCR-ligand 
screening methods that rely on measuring functional responses 
(e.g., calcium mobilization or chemotaxis), rather than bind-
ing, per se, to identify   “  hits  ”  . Although there are   >  100 or-
phan heptahelical GPCR sequences that have been identifi  ed 
via genome sequencing (  41  ), the phylogenetic homology of 
CCRL2 with CC chemokine receptors, and its expression at 
the RNA level by LPS activated macrophages, suggested that 
CCRL2 may be a modulator of leukocyte traffi   cking. In-
deed, we show herein that the expression of CCLR2 by mast 
cells can enhance the numbers of leukocytes in the dermis at 
sites of IgE-dependent cutaneous infl  ammation (  Fig. 4 D  ). 
The identifi  cation of chemerin as a nonsignaling ligand for 
CCRL2 introduces a novel functionality for atypical recep-
tors (i.e., concentration and presentation, as we have shown 
herein for CCRL2, as opposed to internalization/degrada-
tion). Our fi  ndings expand the possible ligand space for atyp-
ical orphan receptors to include chemoattractants beyond 
the chemokine family and provide a potential link between 
CCRL2 expression and chemerin-dependent eff  ects on in-
fl  ammation that are mediated via the cell-signaling chemerin 
receptor CMKLR1. 
  MATERIALS AND METHODS 
  Antibodies and reagents.     Anti-mouse CD11b, CD14, CD19, B220, Gr1, 
and TCR      dye-linked mAb were obtained from eBioscience. Anti-mouse 
CD11c, c-kit, CD49b, and TER119 dye-linked mAb were obtained from 
BD Biosciences. Anti-mouse F4/80 FITC was obtained from AbD Serotec. 
Anti-rat phycoerythrin (human and mouse adsorbed) was purchased from 
BD Biosciences, anti-His  6   phycoerythrin was purchased from R  &  D Sys-
tems, purifi  ed Fc block (mouse anti  –  mouse CD16.2/32.2) was purchased 
from Invitrogen, anti-mCMKLR1 (BZ194) was prepared in house, and 
mouse IgG, rat IgG, and goat serum were purchased from Sigma-Aldrich. 
CCL2-5,7-9,11,16,17,19-22,25,28; CXCL1,2,3,9,10,12,13,16; IL-4; GM-
CSF; and Flt-3 ligand were purchased from R  &  D Systems. Mouse CCL2 
engrafted with WT vs. KO BMCMCs) were at 30 min after 
i.v. antigen challenge, an interval which is too short to ob-
serve substantial recruitment of circulating leukocytes to the 
site of the reaction. Perhaps mast cell  –  bound and then acti-
vated chemerin interacts with CMKLR1  +   macrophages or 
other mononuclear cells that might be present in normal 
skin, and such cells in turn have eff  ects that can enhance 
local vascular permeability. Alternatively, other cell types 
normally resident in the skin, such as vascular endothelial 
cells, may respond to locally activated chemerin. The reduced 
leukocyte numbers present in the dermis 6 h after the elicita-
tion of IgE-dependent PCA reactions in mice whose dermal 
mast cells lacked CCLR2 indicates that a lack of mast cell 
CCLR2 also can diminish the longer term consequences 
of IgE-dependent cutaneous reactions, perhaps by multiple 
mechanisms (which are yet to be defi  ned). Mast cells them-
selves are CMKLR1         (Fig. S11). Notably, the infl  ammation 
associated with relatively strong PCA reactions was not sub-
stantially aff  ected by the presence of absence of CCRL2, 
whether on all cells types (Fig. S4A) or only on skin mast 
cells (Fig. S4, B and C). Thus, whatever contribution mast 
cell  –  associated CCRL2 makes to the tissue swelling and leu-
kocyte infi  ltrates associated with PCA responses appears to 
enhance tissue sensitivity to suboptimal IgE-dependent mast 
cell activation. 
  Treatment of peritoneal macrophages with proinfl  amma-
tory cytokines (IFN-      and TNF     ) or TLR ligands (LPS and 
poly:IC but not CpG) up-regulates CCRL2 expression (Fig. 
S2 A) (  3  ). We observed synergistic eff  ects on receptor up-
regulation when TNF      or IFN-      treatment was combined 
with LPS. An analysis of transcription factor binding sites re-
vealed an interferon-stimulated response element (ISRE) up-
stream of the CCRL2 promoter, which is conserved among 
mammals and may be responsible for the IFN-       –  mediated 
regulation of gene expression in macrophages (Fig. S2 B). 
LPS and IFN-      did not infl  uence CCRL2 expression on 
similarly treated peritoneal mast cells (unpublished data). The 
constitutive expression of CCRL2 on freshly isolated mast 
cells and the regulated expression of CCRL2 on macrophages 
indicates that there can be cell type  –  specific regulation 
of CCRL2 gene expression. Furthermore, it is interesting 
to note that CCRL2 and CMKLR1 on macrophages are re-
ciprocally regulated (e.g., LPS causes down-regulation of 
CMKLR1 but up-regulation of CCRL2 (Fig. S2 A) (  23  ). 
Our data indicate that at some point before 24 h after activa-
tion by TLR ligands or proinfl  ammatory cytokines, macro-
phages can concurrently express both chemerin receptors 
CMKLR1 and CCRL2. The functional consequence of this 
is under investigation. 
  CCRL2 may play distinct physiological roles depending 
on the cellular context of its expression. In a general survey 
of mouse tissues, mCCRL2 is expressed at the RNA level in 
the lung, heart, and spleen, with minimal expression in the 
brain or thymus (Fig. S12, available at http://www.jem.org/
cgi/content/full/jem.20080300/DC1). CCRL2 expression 
by stromal cells in the lung and heart may serve to maintain a JEM VOL. 205, September 29, 2008 
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The cells were resuspended in 10 ml PBS and underlaid with 5 ml NycoPrep 
1.077A (Axis-Shield). After centrifugation,     140,000 high-density mast 
cells were recovered at the bottom of the tube (along with     100,000 con-
taminating RBCs). For functional assays using primary mast cells, peritoneal 
lavage was performed using Tyrode  ’  s solution, and the cells were kept at 
room temperature throughout harvest. 
  Cell sorting and Wright-Giemsa stain.     Mouse peritoneal cells were 
stained as described and sorted by standard fl   ow cytometric techniques 
(FACSVantage; BD Biosciences; fl  ow cytometry was performed at the Stan-
ford University Digestive Disease Center Core Facility, VA Hospital, Palo 
Alto, CA). 1  –  5   ×   10  4   sorted cells were loaded into cytospin chambers and 
centrifuged onto glass slides. The slides were stained with Wright-Giemsa 
dye by standard automated techniques at the VA Hospital Hematology Lab-
oratory (Palo Alto, CA) and examined by light microscopy with a 40  ×   ob-
jective (CX-2; Olympus). 
  RNA expression analysis.     RNA from the indicated tissues or cells was 
extracted using an RNeasy kit per the supplier  ’  s instructions (QIAGEN). 
Gene expression was determined by quantitative PCR using a real-time 
PCR instrument (7900HT; Applied Biosystems) equipped with a 384-well 
reaction block. 0.3  –  1.0   μ  g of total RNA was used as a template for cDNA 
synthesis using MMLV Reverse transcription (Applied Biosystems) with 
oligo dT primers, according to the supplier  ’  s instructions. The cDNA was 
diluted and amplifi  ed by quantitative PCR in triplicate wells using 10 pmols 
of gene specifi  c primers in a total volume of 10   μ  l with Power SYBR Green 
qPCR Master Mix (Applied Biosystems), according to manufacturer  ’  s in-
structions. CCRL2 gene expression was normalized to   cyclophilin A   (  cycA  ) 
levels in each tissue and displayed relative to CCRL2 expression levels de-
tected in the spleen using the 2  -          CT   method (  46  ). Primers used were the 
following: m  CCRL2   5     , ttccaacatcctcctccttg; m  CCRL2   3     , gatgcacgcaa-
caataccac;   cycA   5     , gagctgtttgcagaccaaagttc; and   cycA   3     , ccctggcacatgaatcctgg. 
An RNA dot blot array was purchased from BD Biosciences, and hybridiza-
tions were performed according to the manufacturer  ’  s recommendation. A 
full-length gel-purifi  ed mCCRL2 cDNA probe was radiolabeled with   32  P 
using Rediprime reagents (GE Healthcare) according to the manufacturer  ’  s 
specifi  cations. 
  Preparation of BMCMCs.     Mouse femoral BM cells were cultured in 
20% WEHI-3 cell conditioned medium (containing IL-3) for 6  –  12 wk, 
at which time the cells were   >  98% c-kit  high   Fc     RI       high   by flow cyto-
metry analysis. 
      -hexosaminidase release assay.     BMCMCs were sensitized with 10   μ  g/
ml of anti-DNP IgE mAb (H1-     -26; reference   47  ) by overnight incubation 
at 37  °  C. The cells were then washed with Tyrode  ’  s buff  er (10 mM Hepes, 
pH 7.4, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl  2 , 1 mM MgCl  2 , 0.1% 
glucose, and 0.1% BSA [fraction V; Sigma Aldrich]) and resuspended at 8   ×   
10  6   cells/ml. 25   μ  l of a 2  ×   concentration of stimuli (fi  nal: 0, 1, 10, and 100 
ng/ml DNP-HSA [Sigma-Aldrich] or 0.1   μ  g/ml PMA [Sigma-Aldrich] + 1 
  μ  g/ml A23187 calcium ionophore [Sigma-Aldrich]) were added to the wells 
of a 96-well V-bottom plate (Costar; Corning), and then 25   μ  l of 8   ×   10  6   
cells/ml IgE-sensitized BMCMCs were added and incubated at 37  °  C for 
1 h. After centrifugation, supernatants were collected. The supernatants from 
nonstimulated IgE-sensitized BMCMCs treated with 50   μ  l of 0.5% (vol/vol) 
Triton X-100 (Sigma-Aldrich) were used to determine the maximal (100%) 
cellular      -hexosaminidase content, to which the experimental samples were 
normalized.      -hexosaminidase release was determined by enzyme immuno-
assay with   p  -nitrophenyl-  N  -acetyl-     -  d  -glucosamine (Sigma-Aldrich) sub-
strate as follows: 10   μ  l of culture supernatant was added to the wells of a 
96-well fl  at-bottom plate. 50   μ  l of 1.3 mg/ml   p  -nitrophenyl-  N  -acetyl-     -  d  -
glucosamine solution in 100 mM sodium citrate, pH 4.5, was added, and 
the plate was incubated at room temperature for 15  –  30 min. Next, 140   μ  l 
of 200 mM glycine, pH 7, was added to stop the reaction, and the OD  405   
was determined. 
biotinylated fl  uorokine kit was purchased from R  &  D Systems. CMFDA, 
Fluo-4-acetoxymethyl (AM), and Pluronic acid F-127 (reconstituted in DMSO) 
were purchased from Invitrogen. Bioactive chemerin peptide (YFPGQ-
FAFS) was synthesized by the Stanford PAN facility. Phosphothioated CpG 
oligonucleotides (  42  ) were purchased from QIAGEN. polyI:C and FMLP 
were purchased from Sigma-Aldrich. LPS (  Escherichia coli   O11:B4-derived) 
was purchased from List Biological Laboratories, Inc. TNF      and IFN-      
were purchased from Roche. CFA and IFA were purchased from Sigma-
  Aldrich. Cytokine levels in culture supernatants were measured by using 
mouse TNF      and IL-6 BD OptEIA ELISA Sets (BD Biosciences). 
  Animals.     The Veterans Aff  airs Palo Alto Health Care System Institutional 
Animal Care and Use Committee (Palo Alto, CA) and the Stanford Univer-
sity Administrative Panel on Laboratory Animal Care (Stanford, CA) ap-
proved all animal experiments. CCRL2 KO mice (Lexicon) were backcrossed 
four generations on the C57BL/6 background. Mast cell defi  cient   Kit  W-sh/Wsh     
mice on the C57BL/6 background (  43  ) were provided by P. Besmer 
(Memorial Sloan-Kettering Cancer Center and Cornell University Gradu-
ate School of Medical Sciences, NY, NY), and WT C57BL/6 mice were 
obtained from Taconic. Wistar Furth rats were obtained from Charles 
River Laboratories. 
  Mammalian expression vector construction and generation of sta-
ble cell lines.     The coding regions of mCCRL2, huCCRL2, mCRTH2, 
and huCCR10 were amplifi  ed from genomic DNA with or without an en-
gineered N-terminal HA tag and cloned into pcDNA3 (Invitrogen). Trans-
fectants were generated and stable lines selected in the mouse pre  –  B 
lymphoma cell line L1.2 or HEK293 cells as previously described (  44  ). 
mCMKLR1 and empty vector L1.2 transfectants were generated as previ-
ously described (  20  ). Transfected cells were, in some cases, treated with 5 mM 
  n  -butyric acid (Sigma-Aldrich) for 24 h before experimentation (  45  ). 
  Generating the anti-mCCRL2 mAbs BZ5B8 and BZ2E3.     The im-
munizing amino-terminal mCCRL2 peptide with the sequence NH  2  -MD-
NYTVAPDDEYDVLILDDYLDNSC-COOH (corresponding to residues 
1  –  24 of mCCRL2, with a nonnative carboxyl-terminal cysteine to facilitate 
conjugation to keyhole limpet hemocyanin [KLH]) was synthesized by the 
Stanford Protein and Nucleic Acid Biotechnology Facility and conjugated to 
KLH according to the manufacturer  ’  s specifi  cations (Thermo Fisher Scien-
tifi  c). Wistar Furth rats were immunized with the mCCRL2 peptide/KLH 
conjugate, fi  rst emulsifi  ed in CFA and then, subsequently, in IFA. Hybrid-
omas producing anti-mCCRL2 mAbs were subcloned, and specifi  city was 
confi  rmed by reactivity with mCCRL2 but not other L1.2 receptor trans-
fectants. An ELISA-based assay (BD Biosciences) was used to assess the IgG  2a        
isotypes of the resulting rat anti  –  mouse CCRL2 mAbs, designated BZ5B8 
and BZ2E3. 
  Harvesting mouse leukocytes.     Mice were given a fatal overdose of anes-
thesia (ketamine/xylazine), as well as an i.p. injection of 100 U heparin 
(Sigma-Aldrich), and blood was collected by cardiac puncture. Up to 1 ml 
of blood was added to 5 ml of 2 mM EDTA in PBS, and 6 ml of 2% dextran 
T500 (GE Healthcare) was added to cross-link RBCs. The mixture was in-
cubated for 1 h at 37  °  C, the supernatant was removed and pelleted, and the 
cells were resuspended in 5 ml of RBC lysis buff  er (Sigma-Aldrich) and in-
cubated at room temperature for 5 min. The cells were pelleted and resus-
pended for use in cell staining. BM cells were harvested by fl  ushing femurs 
and tibias with media followed by RBC lysis. Peritoneal lavage cells were 
obtained by i.p. injection of 10 ml PBS, gentle massage of the peritoneal 
cavity, and collection of the exudate. For some experiments, 500   μ  l of peri-
toneal cells (2   ×   10  6   cells/ml) were incubated for 24 h with 1   μ  g/ml LPS, 
10 ng/ml TNF     , 100 U/ml IFN-     , 20   μ  g/ml polyI:C, 10  –  100   μ  g/ml CpG, 
or 5 ng/ml TGF     . For mast cell RNA isolation, peritoneal mast cells were 
enriched for by density centrifugation. Approximately 140 million perito-
neal exudate cells were harvested from nine male WT mice   >  1 yr of age. 2218 ROLE OF CCRL2 IN I  G  E-DEPENDENT INFLAMMATION   | Zabel et al. 
where the underlined residues are nonnative. The proteins were lyophilized 
and checked for purity using electrospray mass spectrometry. 
  Chemerin binding assays.     For chemerin binding/anti-mCCRL2 mAbs 
displacement assays, total peritoneal exudate cells were incubated with vari-
ous concentrations of chemerin or CCL2 for 5 min on ice in binding buff  er, 
washed with PBS, and stained with primary antibodies (either anti-mCCRL 
BZ2E3 or IgE, + Fc block) for 45 min on ice. The cells were washed in PBS 
and stained with secondary anti-rat IgG PE or anti-mouse IgE PE (+ goat 
IgG) for 30 min on ice, washed with PBS, stained with directly conjugated 
F4/80 and c-kit mAbs, and analyzed by fl  ow cytometry. For radioligand 
binding assays, radioiodinated chemerin (residues 21  –  148; R  &  D Systems; 
custom radiolabeling performed by PerkinElmer) was provided as a gift from 
J. Jaen (ChemoCentryx, Mountain View, CA). The specifi  c activity of the 
  125  I-labeled chemerin was 97 Ci/g. For competition binding assays, L1.2 
cells transfected with huCCRL2, mCCRL2, or mCMKLR1 were plated 
into 96-well plates at 0.5   ×   10  6   cells/well. Cells were incubated in binding 
buff  er (Hanks + 0.5% BSA) for 3 h at 4  °  C shaking with 1 nM   125  I-chemerin 
and increasing concentrations of chemerin, His  8  -tagged chemerin, or pep-
tide (9-aa YFPGQFAFS, corresponding to chemerin residues 149  –  157) as 
competitors. For saturation binding assays, mCCRL2/L1.2 cells were plated 
at 0.5   ×   10  6   cells/well. Nonspecifi  c binding was measured in the presence of 
100 nM cold chemerin. Binding was terminated by washing the cells in sa-
line buff  er, and bound radioactivity was measured. Data were analyzed using 
Prism (GraphPad Software, Inc.). Binding data (triplicate or quadruplicate 
wells) were fi  tted to one-site binding hyperbola for saturation assays or to a 
one-site competition curve for competition assays. For direct chemerin 
binding immunofl  uorescence assays, mCCRL2-HA, huCCRL2-HA, mC-
MKLR1-HA, and mCRTH2-HA L1.2 transfectants were incubated for 
30 min on ice with 10 nM His  8  -tagged serum form human chemerin and the 
indicated concentration of untagged chemerin in binding buff  er (PBS with 
0.5% BSA and 0.02% azide). The cells were then washed with PBS and in-
cubated with anti-His  6   PE (+ 2% goat serum) for 30 min on ice, washed, and 
analyzed by fl  ow cytometry. Similar binding experiments were performed 
on total WT or CCRL2 KO peritoneal exudate cells with the indicated 
combinations and concentrations of proform or serum form His  8  -tagged or 
untagged chemerin. After chemerin binding, the cells were stained with di-
rectly conjugated F4/80 and c-kit mAbs and analyzed by fl  ow cytometry. 
  In vitro transwell chemotaxis.     For migration experiments using cell 
lines, 2.5   ×   10  5   cells/100   μ  l chemotaxis media (RPMI + 10% FCS) were 
added to the top wells of 5-  μ  m pore transwell inserts (Costar; Corning), 
and test samples in 600   μ  l media were added to the bottom wells. After in-
cubating the transwell plates for 1.5 h at 37  °  C, the bottom wells were har-
vested and fl  ow cytometry was used to assess migration. For primary cell 
chemotaxis, 10  6   cells/100   μ  l were added to the top well and, after a 2-h in-
cubation at 37  °  C, polystyrene beads (15.0   μ  m diameter; Polysciences, Inc.) 
were added to each well to facilitate normalization of the cell count. The 
cells were then stained for c-kit, F4/80, and/or CD11b expression and ana-
lyzed by fl  ow cytometry. A ratio was generated and percent input migration 
was calculated. 
  Intracellular calcium mobilization.     Chemoattractant-stimulated Ca  2+   
mobilization was performed according to Alliance for Cell Signaling proto-
col ID PP00000210. Cells (3   ×   10  6  /ml) were loaded with 4   μ  M Fluo4-AM 
and 0.16% Pluronic acid F-127 (Invitrogen) in modifi  ed Iscove  ’  s medium 
(Iscove  ’  s medium with 1% heat-inactivated bovine calf serum and 2 mM 
L-glutamine; Invitrogen) for 30 min at 37  °  C. The samples were mixed every 
10 min during loading, washed once, resuspended at up to 2   ×   10  6  /ml in the 
same buff  er, and allowed to rest in the dark for 30 min at room temperature. 
Chemoattractant-stimulated change in Ca  2+  -sensitive fl  uorescence of Fluo-4 
was measured over real-time with a FACScan fl  ow cytometer and CellQuest 
software (BD Biosciences) at room temperature under constant stirring at 
500 rpm. Fluorescent data were acquired continuously up to 1,024 s at 1-s 
intervals. The samples were analyzed for 45 s to establish basal state, removed 
  T cell  –  mast cell coculture.     For CD3  +   T cell purifi  cation, a single cell 
suspension of spleen cells was prepared, and RBCs were lysed (RBC lysing 
buff  er). Spleen cells were incubated with biotinylated anti  –  mouse B220, Gr-1, 
CD11b, CD11c, CD49b, Ter119, and c-kit for 20 min at 4  °  C. The cells 
were then washed and incubated with streptavidin-beads (Miltenyi Biotec) 
for 20 min at 4  °  C, washed again, and passed through a magnetic cell-sorting 
column (MACS column; Miltenyi Biotec), yielding   >  95% CD3  +   T cells. T 
cells were cocultured with mast cells as described previously (  32  ). BMCMCs 
were sensitized with 1   μ  g/ml of anti-DNP IgE mAb at 37  °  C overnight. Af-
ter IgE sensitization, BMCMCs were treated with mitomycin C (50   μ  g/10  7   
cells; Sigma-Aldrich) for 15 min at 37  °  C. BMCMCs and T cells were sus-
pended in RPMI 1640 media (Cellgro; Mediatech, Inc.) supplemented with 
50   μ  M 2-mercaptoethanol (Sigma-Aldrich), 50   μ  g/ml streptomycin (Invit-
rogen), 50 U/ml penicillin (Invitrogen), and 10% heat inactivated FCS 
(Sigma-Aldrich). 0.25   ×   10  5   T cells/well were plated in a 96-well fl  at-bot-
tom plate (BD Biosciences) coated with 1   μ  g/ml anti  –  mouse CD3 (clone 
145-2C11; BD Biosciences) or hamster IgG (eBioscience; in some experi-
ments, anti-CD3 (     ) indicates the substitution of control IgG for anti-CD3), 
and mitomycin C-treated IgE-sensitized or nonsensitized BMCMCs (0.25   ×   
10  5   cells/well) in the presence or absence of 5 ng/ml DNP-HSA at 37  °  C for 
72 h. Proliferation was assessed by pulsing with 0.25   μ  Ci   3  H-thymidine (GE 
Healthcare) for 6 h, harvesting the cells using Harvester 96 Mach IIIM 
(Tomtec, Inc.) and measuring incorporated   3  H-thymidine using a Micro 
Beta System (GE Healthcare). 
  PCA reaction.     Experimental PCA was performed as previously described 
(  48  ), with minor modifi  cations. Mice were injected intradermally with 20   μ  l 
of either anti-DNP IgE mAb (H1-     -26; 5, 50, or 150 ng) in the left ear skin 
or vehicle alone (Pipes-HMEM buff  er) in the right ear skin. The next day, 
mice received 200   μ  l of 1 mg/ml DNP-HSA (200   μ  g/mouse) i.v. Ear thick-
ness was measured before and at multiple intervals after DNP-HSA injection 
with an engineer  ’  s microcaliper (Ozaki). For BMCMC engraftment experi-
ments, BMCMCs were generated from either WT or LCCR KO mice, and 
10  6   cells in 40   μ  l DMEM were injected into the ear skin of mast cell  –  defi  -
cient   Kit  W-sh/Wsh     mice. 6  –  8 wk later, the mice were subjected to experimental 
PCA. After the assay, the mast cells in the ear skin were enumerated in for-
malin-fi  xed paraffi   n-embedded toluidine blue  –  stained sections to evaluate 
the extent of engraftment. In some experiments, formalin-fi  xed paraffi   n-
embedded hematoxylin and eosin  –  stained sections were examined to enu-
merate numbers of leukocytes present in the dermis. In all histological 
studies, examination of the slides was performed by an observer who was not 
aware of the identity of individual sections. 
  FITC-induced contact hypersensitivity (CHS).     FITC-induced CHS 
was performed as described previously (  34  ) with minor modifi  cations. Mice 
were shaved on abdomen 2 d before FITC sensitization. Mice were then 
treated with 200   μ  l of 2.0% (wt/vol) FITC isomer I (Sigma-Aldrich) sus-
pension in acetone-dibutyl phthalate (1:1). 5 d after sensitization with 2.0% 
FITC, mice were challenged with 40   μ  l of vehicle alone to the right ear 
(20   μ  l to each side) and 0.5% (wt/vol) FITC solution to the left ear (20   μ  l 
to each side). Each mouse was housed in a separate cage to prevent contact 
with each other after FITC challenge. Ear thickness was measured before 
and at multiple intervals after FITC challenge with an engineer  ’  s microcali-
per (Ozaki). 
  Chemerin expression and purifi  cation using baculovirus.     The follow-
ing carboxyl-terminal His  8  -tagged proteins were expressed using baculovirus-
infected insect cells as previously described (  27  ):   “  serum form  ”   human 
chemerin (NH  2  -ADPELTE  …  FAPHHHHHHHH-COOH),   “  proform  ”   hu-
man chemerin (NH  2  -ADPELTE  …  LPRSPHHHHHH-COOH), and serum 
form mouse chemerin (NH  2  -ADPTEPE  …  FAPHHHHHHHH-COOH). 
Because certain experiments required nontagged proteins, the His  8   tag was 
proteolytically removed by treatment with carboxypeptidase A (Sigma-Al-
drich), generating the respective proteins NH  2  -  ADP  ELTE  …  FA  PH  -COOH, 
NH  2  -  ADP  ELTE  …  RS  PH  -COOH, and NH  2  -  ADP  TEPE  …  FA  PH  -COOH, JEM VOL. 205, September 29, 2008 
ARTICLE
2219
  We thank Mindy Tsai, Kareem Graham, and J. Zabel for helpful discussions. We 
thank Dan Dairaghi, Tim Sullivan, Niky Zhao, and Susanna Lew  é  n for assistance with 
the radioligand binding assays. 
  E.C. Butcher, B.A. Zabel, T. Ohyama, and J. Pan are supported by grants from the 
National Institutes of Health (AI-59635, AI-47822, and GM-37734), Specialized 
Center of Research (HL-67674), and Digestive Disease Center (DK-56339) and a 
Merit Award from the Veterans Administration to E.C. Butcher. S.J. Galli, S. Nakae, 
and H. Suto are supported by grants from the National Institutes of Health 
(HL-67674, AI-23990, AI-070813, and CA-72074). T.M. Handel is supported by grants 
from the National Institutes of Health (AI37113-09) and the California HIV/AIDS 
Research Program (ID06-SD-206). L. Zuniga is support by a National Institutes of 
Health pre-doctoral fellowship (AI073198). J.-Y. Kim was supported by the Serono 
Foundation and the Cancer Research Institute. C. Alt was supported by the 
Deutsche Forschungsgemeinschaft. S.J. Allen is supported by a California HIV/AIDS 
Research Program fellowship award (TF06-SD-501). 
  The authors have no confl  icting fi  nancial interests. 
Submitted:   13 February 2008 
Accepted:   21 August 2008 
  REFERENCES 
       1  .   Fan  ,   P.  ,   H.     Kyaw  ,   K.     Su  ,   Z.     Zeng  ,   M.     Augustus  ,   K.C.     Carter  , and   Y.   
  Li  .   1998  .   Cloning and characterization of a novel human chemokine 
receptor.       Biochem. Biophys. Res. Commun.       243  :  264    –    268  .    
       2  .   DeVries  ,   M.E.  ,   A.A.     Kelvin  ,   L.     Xu  ,   L.     Ran  ,   J.     Robinson  , and   D.J.   
  Kelvin  .   2006  .   Defi  ning the origins and evolution of the chemokine/
chemokine receptor system.       J. Immunol.       176  :  401    –    415  .   
       3  .   Shimada  ,   T.  ,   M.     Matsumoto  ,   Y.     Tatsumi  ,   A.     Kanamaru  , and   S.     Akira  . 
  1998  .   A novel lipopolysaccharide inducible C-C chemokine receptor 
related gene in murine macrophages.       FEBS Lett.       425  :  490    –    494  .    
       4  .   Brouwer  ,   N.  ,   M.W.     Zuurman  ,   T.     Wei  ,   R.M.     Ransohoff    ,   H.W.   
  Boddeke  , and   K.     Biber  .   2004  .   Induction of glial L-CCR mRNA ex-
pression in spinal cord and brain in experimental autoimmune encepha-
lomyelitis.       Glia      .     46  :  84    –    94  .    
       5  .   Zuurman  ,   M.W.  ,   J.     Heeroma  ,   N.     Brouwer  ,   H.W.     Boddeke  , and   K.   
  Biber  .   2003  .   LPS-induced expression of a novel chemokine receptor 
(L-CCR) in mouse glial cells in vitro and in vivo.       Glia      .     41  :  327    –    336  .    
       6  .   Oostendorp  ,   J.  ,   M.N.     Hylkema  ,   M.     Luinge  ,   M.     Geerlings  ,   H.     Meurs  , 
  W.     Timens  ,   J.     Zaagsma  ,   D.S.     Postma  ,   H.W.     Boddeke  , and   K.     Biber  . 
  2004  .   Localization and enhanced mRNA expression of the orphan che-
mokine receptor L-CCR in the lung in a murine model of ovalbumin-
induced airway infl  ammation.       J. Histochem. Cytochem.       52  :  401    –    410  .   
       7  .   Migeotte  ,   I.  ,   J.D.     Franssen  ,   S.     Goriely  ,   F.     Willems  , and   M.     Parmentier  . 
  2002  .   Distribution and regulation of expression of the putative human 
chemokine receptor HCR in leukocyte populations.       Eur. J. Immunol.     
  32  :  494    –    501  .    
       8  .   Galligan  ,   C.L.  ,   W.     Matsuyama  ,   A.     Matsukawa  ,   H.     Mizuta  ,   D.R.     Hodge  , 
  O.M.     Howard  , and   T.     Yoshimura  .   2004  .   Up-regulated expression and 
activation of the orphan chemokine receptor, CCRL2, in rheumatoid 
arthritis.       Arthritis Rheum.       50  :  1806    –    1814  .    
       9  .   Biber  ,   K.  ,   M.W.     Zuurman  ,   H.     Homan  , and   H.W.     Boddeke  .   2003  . 
  Expression of L-CCR in HEK 293 cells reveals functional responses to 
CCL2, CCL5, CCL7, and CCL8.       J. Leukoc. Biol.       74  :  243    –    251  .    
        10  .   Mantovani  ,   A.  ,   R.     Bonecchi  , and   M.     Locati  .   2006  .   Tuning infl  amma-
tion and immunity by chemokine sequestration: decoys and more.       Nat. 
Rev. Immunol.       6  :  907    –    918  .    
        11  .   Comerford  ,   I.  ,   W.     Litchfi  eld  ,   Y.     Harata-Lee  ,   R.J.     Nibbs  , and   S.R.   
  McColl  .   2007  .   Regulation of chemotactic networks by   ‘  atypical  ’   recep-
tors.       Bioessays      .     29  :  237    –    247  .    
        12  .   Haraldsen  ,   G.  , and   A.     Rot  .   2006  .   Coy decoy with a new ploy: inter-
ceptor controls the levels of homeostatic chemokines.       Eur. J. Immunol.     
  36  :  1659    –    1661  .    
        13  .   Weber  ,   M.  ,   E.     Blair  ,   C.V.     Simpson  ,   M.     O  ’  Hara  ,   P.E.     Blackburn  ,   A.     Rot  , 
  G.J.     Graham  , and   R.J.     Nibbs  .   2004  .   The chemokine receptor D6 con-
stitutively traffi   cs to and from the cell surface to internalize and degrade 
chemokines.       Mol. Biol. Cell      .     15  :  2492    –    2508  .    
        14  .   Hadley  ,   T.J.  , and   S.C.     Peiper  .   1997  .   From malaria to chemokine recep-
tor: the emerging physiologic role of the Duff  y blood group antigen.   
    Blood      .     89  :  3077    –    3091  .   
from the nozzle to add the stimuli, and then returned to the nozzle. Mean 
channel fl  uorescence over time was analyzed with FlowJo software (Tree 
Star, Inc.). In some experiments, to identify mast cells, mixed peritoneal leu-
kocytes were preincubated with c-kit-PerCP mAb for 3 min immediately 
before the start of each sample. In other experiments, mCCRL2HA/L1.2 or 
empty vector pcDNA3/L1.2 cells were loaded for 30 min with 1,000 nM of 
serum form chemerin (incubated in binding buff  er on ice), washed two 
times with PBS, and resuspended in Iscove  ’  s media at 2   ×   10  6  /ml. 500   μ  l of 
these chemerin-loaded cells were added to mCMKLR1/L1.2 cells loaded 
with Fluo4-AM, and calcium mobilization was evaluated. 
  Receptor internalization assay.     mCMKLR1-HA, huCCRL2-HA, and 
mCCRL2-HA L1.2 transfectants were incubated for 15 min with 100 nM 
serum form chemerin at the indicated temperature in cell culture media. The 
cells were then washed with 200   μ  l PBS and stained with mouse anti-HA 
(Covance) or mIgG1 isotype control, followed by staining with secondary 
anti  –  mouse IgG1 PE, fi  xed, and analyzed by fl  ow cytometry. 
  Ligand-independent receptor internalization assay.     mCMKLR1-HA 
and mCCRL2-HA L1.2 transfectants were loaded for 30 min on ice with 
primary antibody (anti-HA or mIgG1 isotype control). The cells were washed 
with 200   μ  l PBS, incubated for the indicated times at 37  °  C to allow for recep-
tor internalization, and then placed on ice. The cells were then incubated 
with secondary anti  –  mouse IgG  1   PE, and analyzed by fl  ow cytometry. 
  Chemerin internalization assay.     mCCRL2-HA L1.2 transfectants or to-
tal peritoneal exudate cells were incubated with 10 nM His  8  -tagged serum 
form chemerin for 30 min on ice. The primary cells were also stained with 
F4/80 and c-kit mAbs. Secondary anti-His  6   PE was added to the cells and 
incubated for 30 min on ice. The cells were then incubated for the indicated 
times at 37  °  C to allow for chemerin internalization. The cells were incu-
bated for 5 min on ice with either PBS or acid wash buff  er (0.2 M acetic acid 
and 0.5 M NaCl) and then analyzed by fl  ow cytometry. Mast cells were 
identifi  ed by gating on SSC  high  F4/80        c-kit  +   cells. 
  Chemerin sequestration assay.     2 nM of serum form chemerin was incu-
bated with 40 million cells of the indicated transfectant lines (or media alone) 
for 15 min at 37  °  C. The cells were removed by centrifugation, and a volume 
of the conditioned media equivalent to 0.2 nM chemerin (barring any se-
questration or degradation) was tested in transwell chemotaxis using mC-
MKLR1-HA/L1.2 cells. 
  Statistics.     The unpaired Student  ’  s   t   test (two-tailed), Mann Whitney   U   test 
(two-tailed), or analysis of variance (ANOVA) was used for statistical evalu-
ation of the results, as indicated. 
  Online supplemental material.     Fig. S1 shows that blood lymphocytes, 
BM neutrophils, and peritoneal macrophages are negative for mCCRL2 ex-
pression. Fig. S2 shows that mCCRL2 is up-regulated on macrophages acti-
vated by specifi  c cytokines and/or TLR ligands. Fig. S3 shows that mCCRL2 
KO mice display a normal contact hypersensitivity response to FITC. Figs. 
S4 and S5 (histology of skin) show that mCCRL2 is dispensable for maximal 
tissue swelling and leukocyte infi  ltration in the dermis in high dose IgE-me-
diated PCA. Fig. S6 shows that mCCRL2/L1.2 transfectants do not migrate 
to CCL2, CCL5, CCL7, or CCL8 in in vitro transwell chemotaxis. Fig. S7 
shows the lack of heterologous displacement of chemerin by other chemoat-
tractants. Fig. S8 shows the displacement of iodinated chemerin (residues 
21  –  148) binding to CCRL2 and CMKLR1 by His  8  -chemerin and bioactive 
chemerin peptide (YFPGQFAFS). Fig. S9 shows the lack of intracellular 
calcium mobilization by CCL2 and/or chemerin in CCRL2/HEK293 
transfectants. Fig. S10 shows an alignment of human and mouse CCRL2 
amino-terminal sequences. Fig. S11 shows the lack of mCMKLR1 expres-
sion on peritoneal mast cells. Fig. S12 shows the mRNA expression profi  le 
of mCCRL2 using a RNA dot blot. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20080300/DC1. 2220 ROLE OF CCRL2 IN I  G  E-DEPENDENT INFLAMMATION   | Zabel et al. 
        32  .   Nakae  ,   S.  ,   H.     Suto  ,   M.     Kakurai  ,   J.D.     Sedgwick  ,   M.     Tsai  , and   S.J.     Galli  . 
  2005  .   Mast cells enhance T cell activation: Importance of mast cell-de-
rived TNF.       Proc. Natl. Acad. Sci. USA      .     102  :  6467    –    6472  .    
        33  .   Takeshita  ,   K.  ,   T.     Yamasaki  ,   S.     Akira  ,   F.     Gantner  , and   K.B.     Bacon  .   2004  . 
  Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 
in contact hypersensitivity induced by fl  uorescein isothiocyanate in the 
mouse.       Int. Immunol.       16  :  685    –    695  .    
        34  .   Suto  ,   H.  ,   S.     Nakae  ,   M.     Kakurai  ,   J.D.     Sedgwick  ,   M.     Tsai  , and   S.J.     Galli  . 
  2006  .   Mast cell-associated TNF promotes dendritic cell migration.       J. 
Immunol.       176  :  4102    –    4112  .   
      35  .   Wershil  ,   B.K.  ,   T.     Murakami  , and   S.J.     Galli  .   1988  .   Mast cell-dependent am-
plifi  cation of an immunologically nonspecifi  c infl  ammatory response. Mast 
cells are required for the full expression of cutaneous acute infl  ammation 
induced by phorbol 12-myristate 13-acetate.       J. Immunol.       140  :  2356    –    2360  .   
        36  .   Martin  ,   T.R.  ,   T.     Takeishi  ,   H.R.     Katz  ,   K.F.     Austen  ,   J.M.     Drazen  , and 
  S.J.     Galli  .   1993  .   Mast cell activation enhances airway responsiveness to 
methacholine in the mouse.       J. Clin. Invest.       91  :  1176    –    1182  .    
        37  .   Bulanova  ,   E.  ,   V.     Budagian  ,   Z.     Orinska  ,   M.     Hein  ,   F.     Petersen  ,   L.     Thon  , 
  D.     Adam  , and   S.     Bulfone-Paus  .   2005  .   Extracellular ATP induces cyto-
kine expression and apoptosis through P2X7 receptor in murine mast 
cells.       J. Immunol.       174  :  3880    –    3890  .   
        38  .   Lau  ,   E.K.  ,   S.     Allen  ,   A.R.     Hsu  , and   T.M.     Handel  .   2004  .   Chemokine-
receptor interactions: GPCRs, glycosaminoglycans and viral chemokine 
binding proteins.       Adv. Protein Chem.       68  :  351    –    391  .    
        39  .   Hata  ,   D.  ,   Y.     Kawakami  ,   N.     Inagaki  ,   C.S.     Lantz  ,   T.     Kitamura  ,   W.N.   
  Khan  ,   M.     Maeda-Yamamoto  ,   T.     Miura  ,   W.     Han  ,   S.E.     Hartman  ,   et 
al  .   1998  .   Involvement of Bruton  ’  s tyrosine kinase in Fc     RI-depen-
dent mast cell degranulation and cytokine production.       J. Exp. Med.     
  187  :  1235    –    1247  .    
        40  .   Fleming  ,   T.J.  ,   E.     Donnadieu  ,   C.H.     Song  ,   F.V.     Laethem  ,   S.J.     Galli  , and 
  J.P.     Kinet  .   1997  .   Negative regulation of Fc     RI-mediated degranulation 
by CD81.       J. Exp. Med.       186  :  1307    –    1314  .    
        41  .   Wise  ,   A.  ,   S.C.     Jupe  , and   S.     Rees  .   2004  .   The identifi  cation of ligands 
at orphan G-protein coupled receptors.       Annu. Rev. Pharmacol. Toxicol.     
  44  :  43    –    66  .    
        42  .   Bauer  ,   M.  ,   V.     Redecke  ,   J.W.     Ellwart  ,   B.     Scherer  ,   J.P.     Kremer  ,   H.   
  Wagner  , and   G.B.     Lipford  .   2001  .   Bacterial CpG-DNA triggers acti-
vation and maturation of human CD11c-, CD123+ dendritic cells.       J. 
Immunol.       166  :  5000    –    5007  .   
        43  .   Tono  ,   T.  ,   T.     Tsujimura  ,   U.     Koshimizu  ,   T.     Kasugai  ,   S.     Adachi  ,   K.   
  Isozaki  ,   S.     Nishikawa  ,   M.     Morimoto  ,   Y.     Nishimune  ,   S.     Nomura  ,   et al  . 
  1992  .   c-kit Gene was not transcribed in cultured mast cells of mast cell-
defi  cient Wsh/Wsh mice that have a normal number of erythrocytes 
and a normal c-kit coding region.       Blood      .     80  :  1448    –    1453  .   
        44  .   Ponath  ,   P.D.  ,   S.     Qin  ,   T.W.     Post  ,   J.     Wang  ,   L.     Wu  ,   N.P.     Gerard  ,   W.   
  Newman  ,   C.     Gerard  , and   C.R.     Mackay  .   1996  .   Molecular cloning and 
characterization of a human eotaxin receptor expressed selectively on 
eosinophils.       J. Exp. Med.       183  :  2437    –    2448  .    
        45  .   Palermo  ,   D.P.  ,   M.E.     DeGraaf  ,   K.R.     Marotti  ,   E.     Rehberg  , and   L.E.   
  Post  .   1991  .   Production of analytical quantities of recombinant proteins 
in Chinese hamster ovary cells using sodium butyrate to elevate gene 
expression.       J. Biotechnol.       19  :  35    –    47  .    
        46  .   Livak  ,   K.J.  , and   T.D.     Schmittgen  .   2001  .   Analysis of relative gene ex-
pression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method.       Methods      .     25  :  402    –    408  .    
        47  .   Liu  ,   F.T.  ,   J.W.     Bohn  ,   E.L.     Ferry  ,   H.     Yamamoto  ,   C.A.     Molinaro  ,   L.A.   
  Sherman  ,   N.R.     Klinman  , and   D.H.     Katz  .   1980  .   Monoclonal dinitro-
phenyl-specifi  c murine IgE antibody: preparation, isolation, and charac-
terization.       J. Immunol.       124  :  2728    –    2737  .   
        48  .   Wershil  ,   B.K.  ,   Z.S.     Wang  ,   J.R.     Gordon  , and   S.J.     Galli  .   1991  . 
  Recruitment of neutrophils during IgE-dependent cutaneous late phase 
reactions in the mouse is mast cell-dependent. Partial inhibition of the 
reaction with antiserum against tumor necrosis factor-alpha.       J. Clin. 
Invest.       87  :  446    –    453  .                      
        15  .   Darbonne  ,   W.C.  ,   G.C.     Rice  ,   M.A.     Mohler  ,   T.     Apple  ,   C.A.     Hebert  ,   A.J.   
  Valente  , and   J.B.     Baker  .   1991  .   Red blood cells are a sink for interleukin 
8, a leukocyte chemotaxin.       J. Clin. Invest.       88  :  1362    –    1369  .    
        16  .   Kashiwazaki  ,   M.  ,   T.     Tanaka  ,   H.     Kanda  ,   Y.     Ebisuno  ,   D.     Izawa  ,   N.   
  Fukuma  ,   N.     Akimitsu  ,   K.     Sekimizu  ,   M.     Monden  , and   M.     Miyasaka  . 
  2003  .   A high endothelial venule-expressing promiscuous chemokine re-
ceptor DARC can bind infl  ammatory, but not lymphoid, chemokines 
and is dispensable for lymphocyte homing under physiological condi-
tions.       Int. Immunol.       15  :  1219    –    1227  .    
        17  .   Middleton  ,   J.  ,   S.     Neil  ,   J.     Wintle  ,   I.     Clark-Lewis  ,   H.     Moore  ,   C.     Lam  ,   M.   
  Auer  ,   E.     Hub  , and   A.     Rot  .   1997  .   Transcytosis and surface presentation of 
IL-8 by venular endothelial cells.       Cell      .     91  :  385    –    395  .    
        18  .   Lee  ,   J.S.  ,   C.W.     Frevert  ,   M.M.     Wurfel  ,   S.C.     Peiper  ,   V.A.     Wong  ,   K.K.   
  Ballman  ,   J.T.     Ruzinski  ,   J.S.     Rhim  ,   T.R.     Martin  , and   R.B.     Goodman  . 
  2003  .   Duff  y antigen facilitates movement of chemokine across the endo-
thelium in vitro and promotes neutrophil transmigration in vitro and in 
vivo.       J. Immunol.       170  :  5244    –    5251  .   
        19  .   Comerford  ,   I.  ,   S.     Milasta  ,   V.     Morrow  ,   G.     Milligan  , and   R.     Nibbs  .   2006  . 
  The chemokine receptor CCX-CKR mediates eff  ective scavenging of 
CCL19 in vitro.       Eur. J. Immunol.       36  :  1904    –    1916  .    
        20  .   Zabel  ,   B.A.  ,   A.M.     Silverio  , and   E.C.     Butcher  .   2005  .   Chemokine-like 
receptor 1 expression and chemerin-directed chemotaxis distinguish 
plasmacytoid from myeloid dendritic cells in human blood.       J. Immunol.     
  174  :  244    –    251  .   
        21  .   Meder  ,   W.  ,   M.     Wendland  ,   A.     Busmann  ,   C.     Kutzleb  ,   N.     Spodsberg  ,   H.   
  John  ,   R.     Richter  ,   D.     Schleuder  ,   M.     Meyer  , and   W.G.     Forssmann  .   2003  . 
  Characterization of human circulating TIG2 as a ligand for the orphan 
receptor ChemR23.       FEBS Lett.       555  :  495    –    499  .    
        22  .   Wittamer  ,   V.  ,   J.D.     Franssen  ,   M.     Vulcano  ,   J.F.     Mirjolet  ,   E.     Le Poul  ,   I.   
  Migeotte  ,   S.     Brezillon  ,   R.     Tyldesley  ,   C.     Blanpain  ,   M.     Detheux  ,   et al  . 
  2003  .   Specifi  c recruitment of antigen-presenting cells by chemerin, a 
novel processed ligand from human infl  ammatory fl  uids.       J. Exp. Med.     
  198  :  977    –    985  .    
        23  .   Zabel  ,   B.A.  ,   T.     Ohyama  ,   L.     Zuniga  ,   J.Y.     Kim  ,   B.     Johnston  ,   S.J.     Allen  , 
  D.G.     Guido  ,   T.M.     Handel  , and   E.C.     Butcher  .   2006  .   Chemokine-like 
receptor 1 expression by macrophages in vivo: Regulation by TGF-beta 
and TLR ligands.       Exp. Hematol.       34  :  1106    –    1114  .    
        24  .   Parolini  ,   S.  ,   A.     Santoro  ,   E.     Marcenaro  ,   W.     Luini  ,   L.     Massardi  ,   F.   
  Facchetti  ,   D.     Communi  ,   M.     Parmentier  ,   A.     Majorana  ,   M.     Sironi  ,   et al  . 
  2007  .   The role of chemerin in the colocalization of NK and dendritic cell 
subsets into infl  amed tissues.       Blood      .     109  :  3625    –    3632  .    
        25  .   Wittamer  ,   V.  ,   B.     Bondue  ,   A.     Guillabert  ,   G.     Vassart  ,   M.     Parmentier  , and 
  D.     Communi  .   2005  .   Neutrophil-mediated maturation of chemerin: a 
link between innate and adaptive immunity.       J. Immunol.       175  :  487    –    493  .   
        26  .   Busmann  ,   A.  ,   M.     Walden  ,   M.     Wendland  ,   C.     Kutzleb  ,   W.G.     Forssmann  , 
and   H.     John  .   2004  .   A three-step purifi  cation strategy for isolation of ham-
ster TIG2 from CHO cells: characterization of two processed endogenous 
forms.       J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.       811  :  217    –    223  .   
        27  .   Zabel  ,   B.A.  ,   S.J.     Allen  ,   P.     Kulig  ,   J.A.     Allen  ,   J.     Cichy  ,   T.M.     Handel  , 
and   E.C.     Butcher  .   2005  .   Chemerin activation by serine proteases of 
the coagulation, fi  brinolytic, and infl  ammatory cascades.       J. Biol. Chem.     
  280  :  34661    –    34666  .    
        28  .   Zabel  ,   B.A.  ,   L.     Zuniga  ,   T.     Ohyama  ,   S.J.     Allen  ,   J.     Cichy  ,   T.M.     Handel  , 
and   E.C.     Butcher  .   2006  .   Chemoattractants, extracellular proteases, and 
the integrated host defense response.       Exp. Hematol.       34  :  1021    –    1032  .    
        29  .   Galli  ,   S.J.  ,   S.     Nakae  , and   M.     Tsai  .   2005  .   Mast cells in the development 
of adaptive immune responses.       Nat. Immunol.       6  :  135    –    142  .    
        30  .   Kraft  ,   S.  ,   S.     Rana  ,   M.H.     Jouvin  , and   J.P.     Kinet  .   2004  .   The role of the 
FcepsilonRI beta-chain in allergic diseases.       Int. Arch. Allergy Immunol.     
  135  :  62    –    72  .    
        31  .   Nakae  ,   S.  ,   H.     Suto  ,   M.     Iikura  ,   M.     Kakurai  ,   J.D.     Sedgwick  ,   M.     Tsai  , 
and   S.J.     Galli  .   2006  .   Mast cells enhance T cell activation: importance 
of mast cell costimulatory molecules and secreted TNF.       J. Immunol.     
  176  :  2238    –    2248  .   